Advice
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder. This is because Alexza Pharmaceuticals did not provide an evidence submission. They consider that there is not enough evidence to provide an evidence submission for this appraisal.
Information
If NHS organisations wish to consider loxapine for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.
ISBN 978-1-4731-0147-0